Product Description
Product Name: Pamorelin LA 22.5 mg Injection
Active Ingredient: Triptorelin Pamoate
Strength: 22.5 mg
Form: Powder for Prolonged-Release Intramuscular Injection
Category: Gonadotropin-Releasing Hormone (GnRH) Agonist
Indication: Prostate Cancer, Endometriosis, Central Precocious Puberty (CPP)
Pamorelin LA 22.5 mg Injection is a long-acting gonadotropin-releasing hormone (GnRH) agonist used for the management of hormone-dependent conditions. It is primarily indicated in the treatment of advanced prostate cancer, and is also effective in managing endometriosis and central precocious puberty (CPP) in children.
Mechanism of Action:
Triptorelin works by suppressing the production of gonadotropins (LH and FSH), leading to a reduction in sex hormone levels such as testosterone in men and estrogen in women. This hormonal suppression helps in slowing disease progression and alleviating symptoms.
